Head of Computational Sciences, Pfizer Research Centers of Emphasis
Greater Boston Area
Head of Computational Sciences, Pfizer Research Centers of Emphasis
Greater Boston Area
Enoch is presently Head of the Computational Sciences Center of Emphasis in Pfizer Research, a global platform function charged with developing computational methods for improved target selection and therapeutic design. External to Pfizer, he is the project manager for the Open Source software package PFAAT and currently serves on the Editorial Advisory Board for Drug Discovery Today and the Steering Group for the Life Sciences Informatics Committee of the Massachusetts Biotechnology Council. He has also served on the external advisory board of the Bioinformatics Program at the Rochester Institute of Technology, the program committee of the Systems Biology discussion group at the New York Academy of Sciences, and on Special Emphasis Panels of study sections for the National Institutes of Health. He is the author of over 25 research articles, scientific reviews, and book chapters.
structural bioinformatics
(Public Company; PFE; Pharmaceuticals industry)
April 2007 — Present (1 year 9 months)
Building a new organization within Pfizer Research based on 5 Pfizer locations and comprising staff with expertise in bioinformatics, computational chemistry, software engineering, scientific data integration, systems architecture, data mining/visualization, and machine learning. We partner with therapeutic area experts and Informatics to design, develop, and deliver tools, systems, models, and applications for improved target selection and therapeutic design.
(Educational Institution; Higher Education industry)
July 2001 — Present (7 years 6 months)
(Public Company; 10,001 or more employees; PFE; Pharmaceuticals industry)
August 2001 — March 2007 (5 years 8 months)
Built and led a group of 16 computational scientists in Cambridge whose expertise spanned the disciplines of bioinformatics, computational chemistry, machine learning/data mining, method development, and software engineering. We worked in the areas of kinase-targeted drug discovery, knowledge management, toxicoinformatics, and large-scale data analysis in partnership with Pfizer experts worldwide.
(Public Company; 10,001 or more employees; PFE; Pharmaceuticals industry)
June 2000 — August 2001 (1 year 3 months)
(Public Company; 10,001 or more employees; MON; Biotechnology industry)
May 1999 — June 2000 (1 year 2 months)
(Educational Institution; Research industry)
1997 — 1999 (2 years)
AB, Molecular Biology
Senior Thesis advisor: Prof. Michael Hecht
PhD, Structural Biology
Doctoral Advisor: Prof. Michael Levitt